China's AI protein design platform company, MoleculeMind, has announced receiving a strategic investment of over 100 million yuan. The investment will be used to further develop their AI protein optimization and design platform, MoleculeOS, and explore its applications in biopharmaceuticals and synthetic biology. MoleculeMind, established just one year ago, has already completed two rounds of financing.

Founded by Professor Xu Jinbo, a prominent computational biologist in the field of AI protein folding, MoleculeMind's research laid the foundation for the development of AlphaFold and demonstrated the possibility of using deep learning methods to predict protein structures.

Drawing on years of team experience, MoleculeMind independently developed the first fully functional AI-driven protein prediction and design platform in China, called "MoleculeOS." This platform utilizes data-driven AI techniques to rapidly identify, modify, and even design the most suitable proteins. It can be applied in the research and design of peptides, antibodies, enzymes, and small proteins, making the development of large-molecule innovative drugs predictable and programmable, thus improving drug development efficiency. Additionally, the platform can also optimize and design proteins in fields such as chemistry, materials, industry, and agriculture, disrupting the research paradigms in the areas of large-molecule drug design, synthetic biology, and environmental protection.

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.